Pancreatic Adenocarcinoma

David P. Ryan, M.D., Theodore S. Hong, M.D., and Nabeel Bardeesy, Ph.D.

Pancreatic ductal adenocarcinoma is the most lethal common cancer because it is usually diagnosed at an advanced stage and is resistant to therapy. In this article, we review current understanding of the biology and treatment of pancreatic adenocarcinoma.

Epidemiology and Risk Factors

Pancreatic adenocarcinoma is rarely diagnosed in persons younger than 40 years of age, and the median age at diagnosis is 71 years. Worldwide, the incidence of all types of pancreatic cancer (85% of which are adenocarcinomas) ranges from 1 to 10 cases per 100,000 people, is generally higher in developed countries and among men, and has remained stable for the past 30 years relative to the incidence of other common solid tumors. It is the eighth leading cause of death from cancer in men and the ninth leading cause of death from cancer in women throughout the world. In the United States this year, pancreatic cancer is expected to develop in 46,000 people, and 40,000 people are expected to die from it.

The risk factors and established genetic syndromes associated with pancreatic adenocarcinoma are shown in Table 1. Although it is estimated that 5 to 10% of pancreatic cancers have an inherited component, the genetic basis for familial aggregation has not been identified in most cases. Among people with a known family history of pancreatic cancer in a first-degree relative, as compared with the general population, the relative risk of the development of pancreatic cancer is increased by a factor of 2, 6, and 30 in people with one, two, and three affected family members, respectively. There is no effective screening tool to detect asymptomatic premalignant or early malignant tumors, and aspirin has not been proved to have a protective effect against pancreatic cancer, as it does against other types of cancer. Although there is consensus regarding the value of screening patients with an inherited predisposition for pancreatic cancer, there is no consensus on the most effective method of screening or the optimal interval between screenings.

Biologic Features of Pancreatic Cancer

Defining features of pancreatic adenocarcinoma include a very high rate of activating mutations in KRAS (>90%), progression from distinct types of precursor lesions, a propensity for both local invasion and distant metastasis, an extensive stromal reaction (desmoplasia) resulting in a hypovascular and hypoxic microenvironment, reprogramming of cellular metabolism, and evasion of tumor immunity.

Molecular pathology studies and extensive genomic analyses have established a model of the progression of pancreatic adenocarcinoma. The signature mutations of pancreatic adenocarcinoma have been identified in microscopic premalignant pancreatic lesions associated with the pancreatic ducts; these findings are referred to as pancreatic intraepithelial neoplasia. As in the model established for the polyp-to-adenocarcinoma sequence in colon cancer, there is a stepwise progression...
Table 1. Risk Factors and Inherited Syndromes Associated with Pancreatic Cancer.\textsuperscript{*}

<table>
<thead>
<tr>
<th>Variable</th>
<th>Approximate Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking\textsuperscript{3}</td>
<td>2–3</td>
</tr>
<tr>
<td>Long-standing diabetes mellitus\textsuperscript{4}</td>
<td>2</td>
</tr>
<tr>
<td>Nonhereditary and chronic pancreatitis\textsuperscript{5}</td>
<td>2–6</td>
</tr>
<tr>
<td>Obesity, inactivity, or both\textsuperscript{6}</td>
<td>2</td>
</tr>
<tr>
<td>Non–O blood group\textsuperscript{7}</td>
<td>1–2</td>
</tr>
</tbody>
</table>

Genetic syndrome and associated gene or genes — %

<table>
<thead>
<tr>
<th>Syndrome</th>
<th>Gene(s)</th>
<th>Approximate Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary pancreatitis (PRSS1, SPINK1)\textsuperscript{8}</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Familial atypical multiple mole and melanoma syndrome (p16)\textsuperscript{9}</td>
<td>10–20</td>
<td></td>
</tr>
<tr>
<td>Hereditary breast and ovarian cancer syndromes (BRCA1, BRCA2, PALB2)\textsuperscript{10,11}</td>
<td>1–2</td>
<td></td>
</tr>
<tr>
<td>Peutz–Jeghers syndrome (STK11 [LKB1])\textsuperscript{12}</td>
<td>30–40</td>
<td></td>
</tr>
<tr>
<td>Hereditary nonpolyposis colon cancer (Lynch syndrome) (MLH1, MSH2, MSH6)\textsuperscript{13}</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Ataxia–telangiectasia (ATM)\textsuperscript{14}</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Li–Fraumeni syndrome (P53)\textsuperscript{15}</td>
<td>Unknown</td>
<td></td>
</tr>
</tbody>
</table>

\textsuperscript{*} Values associated with risk factors are expressed as relative risks, and values associated with genetic syndromes are expressed as lifetime risks, as compared with the risk in the general population.

of pancreatic intraepithelial neoplasia from low grade to high grade in types 1, 2, and 3. These types are associated with accumulating genetic alterations. In autopsy series, low-grade pancreatic intraepithelial neoplasia type 1 lesions are readily detectable in the nondiseased pancreas, whereas more advanced lesions are typically detected adjacent to established adenocarcinomas or in the non–tumor-bearing pancreas in patients with a familial predisposition to pancreatic cancer.\textsuperscript{21} More than 90% of cases of pancreatic intraepithelial neoplasia of all grades have KRAS mutations.\textsuperscript{22} The mutational inactivation of the CDKN2A, p53, and SMAD family member 4 (SMAD4) tumor suppressors is detected with increasing frequency in type 2 and type 3 lesions of pancreatic intraepithelial neoplasia, suggesting that KRAS mutations contribute to its inception and that the subsequent mutations are rate-limiting events for tumor progression.\textsuperscript{23} Genetically engineered mouse models are consistent with this model of genetic progression.\textsuperscript{24}

Recent exome-sequencing studies have identified additional loss-of-function mutations encoding components of the SWI/SNF nucleosome remodeling complex, which are cumulatively detected in approximately 10 to 15% of pancreatic adenocarcinomas, as well as other, less frequent alterations.\textsuperscript{25} Since these are alterations of tumor-suppressor genes, they have not yet led to hypotheses for therapeutic interventions. Beyond these mutational events, the pancreatic adenocarcinoma genome is characterized by diverse, large-scale chromosomal changes with frequent amplifications, deletions, and rearrangements.

Intraductal papillary mucinous neoplasms are a second type of precursor to pancreatic cancer. These radiographically detectable cystic tumors are relatively common (occurring in approximately 2% of adults and in up to 10% of persons 70 years of age or older), and they have heterogeneous histologic and clinical features. Although most intraductal papillary mucinous neoplasms are asymptomatic, these tumors are associated with an overall risk of invasive cancer of approximately 25%, and those arising from the main pancreatic duct have considerably higher malignant potential than those arising from the branch duct. Like pancreatic epithelial neoplasms, intraductal papillary mucinous neoplasms frequently harbor KRAS mutations (in 40 to 65% of cases) (Fig. 1).\textsuperscript{26} In addition, 40 to 80% have activating mutations in GNAS (encoding the G-protein subunit αs, which activates adenylyl cyclase, leading to cyclic AMP production), and more than 50% have inactivation of RNF43 (an antagonist of Wnt signaling); the effect of these mutations is unknown.

The majority of genomics analyses have focused on resected pancreatic adenocarcinoma, which accounts for only approximately 15% of cases. Exome sequencing from a rapid autopsy program in which patients with pancreatic cancer had provided consent for an autopsy to be performed immediately after death has shown considerable intratumoral genomic heterogeneity, with multiple distinct subclones arising from a common originating cell, as has been noted in other types of cancer.\textsuperscript{27} Also, the primary tumors and the metastatic deposits obtained from the same patient have largely overlapping genomic features. Nevertheless, metastases arise from distinct subclones within the primary tumor. A high metastatic burden (ranging from 10 to 1000 metastatic nodules) is strongly associated with the presence of inactivating SMAD4 (DPC4) mutations. Studies of resected specimens have shown that these mutations predict shortened survival. In addition, alterations in P53 further subdivide
the metastatic phenotype into distinct genetic subsets.

As the most common oncogenic mutation in pancreatic adenocarcinoma, KRAS activation has been investigated in depth for its contributions to the tumorigenic growth of established cancers. Several studies have shown that the KRAS mutation is a marker of a poor prognosis in both patients with resectable tumors and those with unresectable tumors. Functional studies have shown that KRAS is critical for the sustained growth of advanced pancreatic adenocarcinoma.

In genetically engineered mouse models in which a mutant KRAS allele can be switched off at any time during tumorigenesis, loss of KRAS expression results in massive cell death and arrested proliferation, leading to rapid tumor regression. Similarly, most human pancreatic adenocarcinoma cell lines are highly sensitized to cell death, arrested proliferation, or both on knockdown of mutant KRAS with the use of RNA interference. Therefore, the targeting of KRAS is the subject of many ongoing preclinical and clinical investigations. In addition, the epidermal growth factor receptor (EGFR) and the Human Epidermal Growth Factor Receptor 2 (HER2) are also important targets for the treatment of pancreatic adenocarcinoma.
**NEW INSIGHTS INTO CELLULAR METABOLISM**

Alterations in cellular metabolism have emerged as targets for therapeutic intervention. Cancers in general have increased metabolic requirements that need to be coordinated with nutrient supply. Pancreatic adenocarcinoma must contend with particularly severe metabolic stress, since the hypovascular, fibrotic tumor microenvironment results in extreme hypoxia and limited nutrient availability. Consequently, a number of acquired alterations in nutrient acquisition and use are required for the growth and survival of pancreatic adenocarcinomas; several of these alterations are controlled directly or indirectly by oncogenic KRAS. KRAS promotes acquisition of extracellular nutrients, including increased glucose uptake, and directs the scavenging of serum lipids and proteins, the latter by an endocytic process known as macropinocytosis. The tumors with KRAS mutations are characterized by constitutively high levels of autophagy, a process by which organelles and protein aggregates are recycled by engulfment in modified membranes (autophagosomes) and degraded in lysosomes. Autophagy can serve both to detoxify the cell by removing damaged components and to provide intermediary metabolites derived from degraded cargo for biosynthesis and energy production. Studies involving cells from both mice and humans show that the growth of pancreatic adenocarcinoma is inhibited by genetic inhibition of autophagy or by chloroquine, which inhibits lysosomal acidification and is currently under investigation in clinical trials.

KRAS also reprograms metabolism by altering the expression of enzymes involved in glucose utilization (Fig. 2). Instead of using glucose to fuel the tricarboxylic acid cycle leading to energy production by oxidative phosphorylation, pancreatic adenocarcinoma cells depend on high levels of glycolysis, which allows for the production of energy and provides the metabolic intermediates for biosynthetic reactions. KRAS in particular directs glucose to be used for nucleotide biosyn-
thesis and protein glycosylation. In addition, KRAS promotes the use of glutamine for both replenishing the tricarboxylic acid cycle and generating NADPH, an antioxidant that mitigates potentially cytotoxic reactive oxygen species generated during cell proliferation.\textsuperscript{38} Finally, KRAS maintains the redox state by inducing the nuclear factor erythroid 2–related factor 2 (Nrf2) transcription factor, a master regulator of antioxidant genes.\textsuperscript{39} Genetic and pharmacologic studies indicate that many of these adaptive changes in metabolism are required for tumorigenicity of pancreatic adenocarcinoma cells and thus are potential targets for therapeutic intervention.

**Pancreatic Stroma and Immunomodulation**

The microenvironment of pancreatic adenocarcinoma has a complex role in tumor growth and therapeutic response.\textsuperscript{20} These cancers are characterized by a dense stroma consisting of proliferating myofibroblasts (pancreatic stellate cells) and deposition of type I collagen, hyaluronic acid, and other extracellular matrix components, as well as multiple types of inflammatory cells, including macrophages, mast cells, lymphocytes, and plasma cells. Factors that are produced in the stroma, such as connective-tissue growth factor, may directly contribute to the survival of tumor cells.\textsuperscript{40} In addition, the microenvironment probably has many indirect effects on disease progression. For example, pancreatic adenocarcinomas have low microvascular density, prominent leaky vasculature, limited perfusion, and consequent intratumoral hypoxia. The fibrous stroma may contribute to this reduced blood flow, and its high interstitial pressure may impair drug delivery.\textsuperscript{41} Clinical trials targeting the pancreatic stromal barrier (e.g., ClinicalTrials.gov number, NCT01839487) are currently under way, including studies of recombinant hyaluronidase, which degrades a major component of the extracellular matrix. However, studies in mouse models have shown that reducing the myofibroblast content accelerates tumorigenesis and results in more aggressive histologic features, indicating that some stromal components restrain tumor growth and highlighting the need for further understanding of the tumor microenvironment.\textsuperscript{42-44}

An additional important characteristic of the microenvironment of pancreatic adenocarcinoma is restriction of immune surveillance and creation of an inflammatory program that supports tumorigenesis through paracrine cross-talk between tumor cells and immune cells.\textsuperscript{45} From the earliest stages of tumor formation, immunosuppressive regulatory T cells and Gr1+CD11b+ myeloid cells are recruited to the tumor stroma, leading to a block in T-cell–mediated antitumor immunity. This recruitment is induced by production of the cytokine granulocyte–macrophage colony-stimulating factor by tumor cells.\textsuperscript{46} Moreover, macrophages with tumorigenic potential are recruited to early and advanced lesions through a process requiring the interleukin–6–Janus kinase–signal transducer and activator of transcription 3 (STAT3) signaling pathway.\textsuperscript{47} These properties of the tumor microenvironment have important implications for immune-based therapies. Remarkably, studies involving genetically engineered mouse models show that targeting chemokine (C-X-C motif) ligand 12 (CXCL12), which is expressed in a subgroup of stromal fibroblasts, synergizes the checkpoint agonists, restoring cytotoxic T-cell recruitment and leading to tumor regression.\textsuperscript{48} An additional approach to reactivating tumor immunity is the use of agonist CD40 antibodies, which have been shown to cause infiltration of pancreatic adenocarcinoma with tumoricidal macrophages in both patients and mouse models.\textsuperscript{49} The use of tumor antigen–targeted vaccines (e.g., a vaccine against mutant KRAS), another immunomodulatory strategy, has shown promise in in mouse models of early but not advanced disease.\textsuperscript{50} Overall, the rapidly evolving field of tumor immunology holds promise for the development of new and more effective strategies to combat pancreatic adenocarcinoma.

### Clinical Presentation, Diagnosis, and Staging

Approximately 60 to 70% of pancreatic cancers are located in the head of the pancreas, and 20 to 25% are located in the body and tail of the pancreas. The presenting signs and symptoms are related to the location.\textsuperscript{51} Patients with pancreatic cancer most commonly present with abdominal pain, weight loss, asthenia, and anorexia.\textsuperscript{52} Jaundice is a common manifestation of tumors in the head of the pancreas. Diabetes is present in at least 50% of patients with pancreatic cancer.\textsuperscript{53} Once a pancreatic mass is detected, abdominal computed tomography with both arterial and venous phases is usually sufficient to determine the initial stage and treatment.\textsuperscript{54} Pancre-
Atopic cancer metastasizes primarily to the liver, abdomen, and lungs. A biopsy of the pancreatic mass is most often accomplished by means of endoscopic ultrasonography. Although the tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) have neither sensitivity nor specificity for use in screening to detect pancreatic cancer, if elevated, they are useful in following patients with known disease.

More than 90% of patients who have received a diagnosis of pancreatic cancer die from the disease. Approximately 70% of these patients die from extensive metastatic disease; the other 30% have limited metastatic disease at the time of death, but many of them have bulky primary tumors. Cachexia associated with pancreatic cancer may not directly correlate with the overall disease burden.

**Management**

**Surgically Resectable Pancreatic Cancer (Stage I or II)**

**Surgery**

Surgical resection is the only potentially curative therapy for pancreatic cancer. Assessment of the primary tumor and involvement of the local vessels, including the celiac artery, superior mesenteric artery and vein, portal vein, and hepatic artery, is critical in determining resectability (Fig. 3). Localized tumors are categorized on a continuum from “resectable” to “unresectable (locally advanced)” according to the involvement of the local vessels. The term “borderline resectable” has gained popularity as a catchall for tumors that elude precise categorization. After careful assessment, only 15 to 20% of patients are considered to be candidates for surgical resection, and many of these patients are found to have microscopically positive margins at the time of surgery.

A pancreaticoduodenectomy (the Whipple procedure) is required to remove tumors in the head and neck of the pancreas. No major difference in outcome has been observed with variations on pancreaticoduodenectomy, including pylorus-preserving, subtotal stomach-preserving, and minimally invasive techniques. In addition, more extensive surgery, including extended lymphadenectomy and arterial en bloc resection, does not improve outcomes. Tumors in the body or tail of the pancreas are removed by means of a distal pancreatectomy, which most often includes a splenectomy. Increasingly, distal tumors are removed by means of a distal pancreatectomy, which most often includes a splenectomy.
being safely resected laparoscopically. A significant correlation between hospital and surgical case volume for pancreatic resection and operative mortality has persisted over time.

**Adjuvant Therapy**

Because of the poor outcomes associated with surgery alone, the role of adjuvant therapy has been extensively evaluated. Adjuvant therapy includes systemic therapy to reduce the risk of distant metastases and chemoradiotherapy to reduce the risk of locoregional failure. A series of studies has established that 6 months of chemotherapy with either gemcitabine or fluorouracil, as compared with observation, improves overall survival (Table 2). Although there is a clear consensus regarding the value of adjuvant chemotherapy, the role of adjuvant radiation therapy is controversial. Two European studies showed no benefit of adjuvant radiation therapy. These studies were criticized for design flaws, and a disagreement has emerged between investigators in Europe and investigators in the United States over the value of radiation therapy for local control. It is the subject of an ongoing randomized trial in the United States (NCT01013649).

**Table 2. Adjuvant Therapy for Pancreatic Cancer.*

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of Patients</th>
<th>Treatment</th>
<th>Survival</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>GITSG</td>
<td>43</td>
<td>Observation, Fluorouracil plus radiotherapy</td>
<td>10% at 2 yr</td>
<td>0.007</td>
</tr>
<tr>
<td>EORTC</td>
<td>218</td>
<td>Observation, Fluorouracil plus radiotherapy</td>
<td>26% at 2 yr</td>
<td>0.10</td>
</tr>
<tr>
<td>ESPAC-1</td>
<td>289</td>
<td>Observation, Fluorouracil plus chemoradiotherapy</td>
<td>16.9 mo (median)</td>
<td>13.9 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONKO-01</td>
<td>368</td>
<td>Observation, Gemcitabine</td>
<td>10.4% at 5 yr</td>
<td>0.01</td>
</tr>
<tr>
<td>ESPAC 3</td>
<td>1088</td>
<td>Fluorouracil, Gemcitabine</td>
<td>23.0 mo (median)</td>
<td>0.39</td>
</tr>
<tr>
<td>RTOG 9704</td>
<td>451</td>
<td>Fluorouracil plus radiotherapy, Gemcitabine</td>
<td>22% at 5 yr</td>
<td>0.12</td>
</tr>
<tr>
<td>JASPAC-01</td>
<td>378</td>
<td>S-1 (oral fluoropyrimidine), Gemcitabine</td>
<td>70% at 2 yr</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

* CONKO-01 denotes Charité Onkologie 01, EORTC European Organization for Research and Treatment of Cancer, ESPAC European Study Group for Pancreatic Cancer, GITSG Gastrointestinal Tumor Study Group, JASPAC-01 Japan Adjuvant Study Group of Pancreatic Cancer, and RTOG 9704 Radiation Therapy Oncology Group 9704.

† The estimated 5-year survival rate was 10% among patients who received chemoradiotherapy and 20% among patients who did not receive chemoradiotherapy (P = 0.05). The 5-year survival rate was 21% among patients who received chemotherapy and 8% among patients who did not receive chemotherapy (P = 0.009).

**Neoadjuvant (Preoperative) and New Approaches**

The high rate of positive lymph nodes and surgical margins at the time of resection has prompted investigators to evaluate preoperative chemoradiotherapy approaches, which have had limited efficacy. Recently, there has been growing interest in incorporating multiagent chemotherapy regimens such as the combination of fluorouracil, irinotecan, oxaliplatin, and leucovorin (FOLFIRINOX) and gemcitabine plus albumin-bound paclitaxel particles (nab-paclitaxel) in preoperative and postoperative regimens on the basis of their activity in patients with metastatic disease (see below). Clinical trials with these regimens are currently under way (NCT01591733, NCT01688336, and NCT01560949).

Investigators have also sought to enhance the immune response against pancreatic cancer with the use of adjuvant therapy. Early trials showed the ability to induce an immune response against pancreatic cancer cells, but this response has not translated into a survival benefit. Newer trials incorporating immune checkpoint inhibitors such as the inhibitors to programmed death 1 (PD-1) and the PD-1 ligand PD-L1 are under way.
**Locally Advanced, Unresectable Pancreatic Cancer (Stage III)**

As with resectable pancreatic adenocarcinoma, the use of radiation therapy as part of the standard management of locally advanced or unresectable pancreatic cancer is controversial because of the conflicting results of randomized studies. Preliminary results of the international LAP-07 (Gemcitabine with or without Capecitabine and/or Radiation Therapy or Gemcitabine with or without Erlotinib in Treating Patients with Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery) study (NCT00634725) were presented at the annual meeting of the American Society of Clinical Oncology in 2013 (http://meetinglibrary.asco.org/content/116391-132). In this trial, 269 patients with stable disease or disease that responded to treatment after 4 months of chemotherapy were randomly assigned to receive chemoradiotherapy or continue chemotherapy. There was no significant difference in overall survival between the groups. Although the final analysis of the study data, including adherence to guidelines for administration of radiation therapy, is ongoing, the initial results have markedly lessened enthusiasm for the use of radiation therapy for locally advanced disease.

Progress in treating localized pancreatic cancer has been limited by inadequate systemic control and poor response rates. FOLFIRINOX and gemcitabine–nab-paclitaxel were recently shown to have a benefit in patients with metastatic disease; thus, there has been increasing interest in evaluating FOLFIRINOX and gemcitabine–nab-paclitaxel in patients with locally advanced disease. Early studies suggest that the likelihood of a radiographic response in patients with an unresectable primary tumor is similar to that seen in patients with metastatic disease.

**Metastatic Pancreatic Cancer (Stage IV)**

Patients with pancreatic cancer often have multiple symptoms, and integrated supportive care is critical in helping patients remain well for as long as possible. Fluorouracil-based chemotherapy, as compared with best supportive care alone, improves survival by approximately 3 months.

In 1996, a study comparing gemcitabine with fluorouracil in patients with advanced pancreatic cancer showed an improvement in overall survival of 1 month among patients receiving gemcitabine. Over the next 10 years, multiple randomized studies compared single-agent gemcitabine with combination therapy and did not show a consistent improvement in survival. In one exception, the addition of the EGFR inhibitor erlotinib was associated with a significant improvement in overall survival of approximately 2 weeks. Because of its limited effect and added

---

**Table 3. Key Clinical Trials in Metastatic Pancreatic Cancer.**

<table>
<thead>
<tr>
<th>Trial</th>
<th>No. of Patients</th>
<th>Treatment</th>
<th>Median Survival (mo)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Burris et al.</td>
<td>126</td>
<td>Fluorouracil</td>
<td>4.4</td>
<td>0.002</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gemcitabine</td>
<td>5.6</td>
<td></td>
</tr>
<tr>
<td>NCIC</td>
<td>569</td>
<td>Gemcitabine</td>
<td>5.9</td>
<td>0.04</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gemcitabine plus erlotinib</td>
<td>6.2</td>
<td></td>
</tr>
<tr>
<td>Ueno et al.</td>
<td>834</td>
<td>Gemcitabine</td>
<td>8.8</td>
<td>&lt;0.001 for non-inferiority</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S-1</td>
<td>9.7</td>
<td></td>
</tr>
<tr>
<td>Conroy et al.</td>
<td>342</td>
<td>Gemcitabine</td>
<td>6.8</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FOLFIRINOX</td>
<td>11.1</td>
<td></td>
</tr>
<tr>
<td>Von Hoff et al.</td>
<td>861</td>
<td>Gemcitabine</td>
<td>6.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Gemcitabine plus nab-paclitaxel</td>
<td>8.5</td>
<td></td>
</tr>
</tbody>
</table>

* FOLFIRINOX denotes fluorouracil, irinotecan, oxaliplatin, and leucovorin; and NCIC National Cancer Institute of Canada.
Pancreatic adenocarcinoma remains one of the most common and deadly cancers. Recent advances in the treatment of metastatic disease are being evaluated in patients with resectable and locally advanced disease. In addition, new insights into the biology and genetics of pancreatic cancer, including new findings regarding KRAS mutations, tumor metabolism, and tumor immunology, may be of value in the development of new treatments.

Dr. Ryan reports receiving fees for serving on an advisory board from MedImmune, consulting fees from Boehringer Ingelheim and Illumina, and travel support from EMD Serono. No other potential conflict of interest relevant to this article was reported.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

We thank Dr. Carlos Fernandez del Castillo for his guidance and mentorship in writing an earlier version of the manuscript.

REFERENCES
lowing pancreatic cancer resection: a randomized controlled trial. JAMA 2010;304:1073-81.


Copyright © 2014 Massachusetts Medical Society.